Latest research report on “Alpha 1 Antitrypsin Deficiency Treatment Market” now available at high quality database of ReportsnReports.com with market size, share, trends, competitive and statistical analysis. An exclusive data offered in this report is collected by research and industry experts team.
Get Free Sample Research Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5612248
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegeners granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
This report contains market size and forecasts of Alpha 1 Antitrypsin Deficiency Treatment in Global, including the following market information:
Global Alpha 1 Antitrypsin Deficiency Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Alpha 1 Antitrypsin Deficiency Treatment market was valued at 1914.5 million in 2021 and is projected to reach US$ 3413.7 million by 2028, at a CAGR of 8.6% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Augmentation Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols and CSL Behring, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Alpha 1 Antitrypsin Deficiency Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Alpha 1 Antitrypsin Deficiency Treatment Market, by Indication, 2017-2022, 2023-2028 ($ millions)
Global Alpha 1 Antitrypsin Deficiency Treatment Market Segment Percentages, by Indication, 2021 (%)
– Augmentation Therapy
– Cystic Fibrosis(CF)
– Non-CF Bronchiectasis(NCFB)
Global Alpha 1 Antitrypsin Deficiency Treatment Market, by End Users, 2017-2022, 2023-2028 ($ millions)
Global Alpha 1 Antitrypsin Deficiency Treatment Market Segment Percentages, by End Users, 2021 (%)
– Cystic Fibrosis(CF)
– Non-CF Bronchiectasis(NCFB)
Global Alpha 1 Antitrypsin Deficiency Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Alpha 1 Antitrypsin Deficiency Treatment Market Segment Percentages, By Region and Country, 2021 (%)
– North America
– – US
– – Canada
– – Mexico
– – Germany
– – France
– – U.K.
– – Italy
– – Russia
– – Nordic Countries
– – Benelux
– – Rest of Europe
– – China
– – Japan
– – South Korea
– – Southeast Asia
– – India
– – Rest of Asia
– South America
– – Brazil
– – Argentina
– – Rest of South America
– Middle East & Africa
– – Turkey
– – Israel
– – Saudi Arabia
– – UAE
– – Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Alpha 1 Antitrypsin Deficiency Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Alpha 1 Antitrypsin Deficiency Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
– Boehringer Ingelheim
– Teva Pharmaceutical Industries
– CSL Behring
– Kamada Ltd
– Chiesi Pharmaceuticals
– Kedrion Group
– Vertex Pharmaceuticals
– ProMetic Life Sciences
More information about Discount offers (20% or More) @ https://www.reportsnreports.com/contacts/discount.aspx?name=5612248
About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
We provide 24/7 online and offline support to our customers.
E-mail: [email protected]
Phone: +1 888 391 5441